Top news

Sep 17, 2026, 02:30 PM UTC

← Latest news

01
ContinuingAI-generated
Global leaders and tech executives clash over artificial intelligence risks

Global leaders and tech executives clash over artificial intelligence risks

Global leaders, tech executives, and experts remain deeply divided on how to address artificial intelligence risks and potential regulatory frameworks.

Debate over artificial intelligence safety has intensified as tech leaders, politicians, and researchers propose contrasting approaches to managing the technology's rapid advancement. Speaking in San Francisco, OpenAI Chief Executive Sam Altman urged the public to trust developers, asserting, "The world should trust that we are going to do the right thing because it's the right thing and we feel the magnitude of this." Conversely, computer scientist Yoshua Bengio warned that mounting safety incidents will force governments into emergency regulation similar to pandemic responses. European Commission President Ursula von der Leyen addressed existential risks while acknowledging limited room for maneuver, and analysts warned of severe disruptions to democracy and labor markets. However, Cypriot officials argued that artificial intelligence represents an opportunity, maintaining that human misuse poses the primary risk.

Sources: BBC News, Cyprus Mail, Politico Europe (Defense), Sweden Herald, The Guardian.

Read more
02
NHS England approves life-extending breast cancer drug Enhertu

NHS England approves life-extending breast cancer drug Enhertu

Patients in England with incurable HER2-low breast cancer gain NHS access to Enhertu after a price agreement was reached.

Thousands of patients in England with a specific form of incurable breast cancer will gain access to the life-extending drug Enhertu on the NHS following a pricing agreement between health officials and manufacturers.

The drug targets HER2-low advanced breast cancer and is expected to benefit around 1,000 women annually. Clinical trial data indicates that Enhertu can extend life by an average of seven months, with some patients surviving up to three years longer.

The decision follows prolonged negotiations after health regulators previously deemed the treatment too costly for routine public healthcare. While patients in Scotland have had access to the drug since 2023, the new agreement brings England in line with dozens of other nations where it is already available.

Sources: BBC Northern Ireland, The Guardian

Read more
03

US Senate blocks landmark digital asset regulation bill

The US Senate failed to advance a procedural vote on a landmark digital asset bill that would have given the CFTC primary oversight over crypto markets.

The US Senate has halted a major digital asset market structure bill following a 49–50 procedural vote. The proposed legislation aimed to establish a comprehensive regulatory framework for the cryptocurrency sector by granting primary supervisory authority to the Commodity Futures Trading Commission.

Following the failed vote, shares in cryptocurrency-related companies experienced a downturn. Despite the legislative setback, industry representatives expressed continued hope regarding future reform efforts. Blockchain Association Chief Executive Summer Mersinger stated she remains "optimistic that crypto will eventually get the regulatory framework it needs." The outcome leaves the division of federal regulatory oversight between American financial agencies unresolved for now.

Sources: Bloomberg.

Read more
Share